{"protocolSection":{"identificationModule":{"nctId":"NCT06470438","orgStudyIdInfo":{"id":"88998377LYM1001"},"secondaryIdInfos":[{"id":"2023-509258-71-00","type":"REGISTRY","domain":"EUCT number"}],"organization":{"fullName":"Janssen Research & Development, LLC","class":"INDUSTRY"},"briefTitle":"A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma","officialTitle":"A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-05-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-10-29","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-10-29","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-17","studyFirstSubmitQcDate":"2024-06-17","studyFirstPostDateStruct":{"date":"2024-06-24","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-17","lastUpdatePostDateStruct":{"date":"2024-06-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Janssen Research & Development, LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The main purpose of this study is to characterize safety and to determine the recommended phase 2 dose (RP2D) for JNJ-88998377 (Part A: Dose Escalation) and to further assess the safety of JNJ-88998377 at the RP2D (Part B: Dose Expansion)."},"conditionsModule":{"conditions":["Lymphoma, Non-Hodgkin","Refractory B-Cell NHL","Relapsed B-cell NHL"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":160,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Part A: Dose Escalation","type":"EXPERIMENTAL","description":"Participants will receive JNJ-88998377 at a selected starting dose. Subsequent dose levels and schedules will be selected based on the review of all available data to establish recommended Phase 2 dose (RP2D).","interventionNames":["Drug: JNJ-88998377"]},{"label":"Part B: Dose Expansion","type":"EXPERIMENTAL","description":"Participants will receive JNJ-88998377 at RP2D determined in Part A. Additional expansion cohort(s) may be added with a lower RP2D(s), or different dose schedule(s) based on all available data.","interventionNames":["Drug: JNJ-88998377"]}],"interventions":[{"type":"DRUG","name":"JNJ-88998377","description":"JNJ-88998377 will be administered.","armGroupLabels":["Part A: Dose Escalation","Part B: Dose Expansion"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Parts A and B: Number of Participants with Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non-investigational) product. It does not necessarily have a causal relationship with the investigational product.","timeFrame":"Upto 3 years 4 months"},{"measure":"Part A: Number of Participants with Dose Limiting Toxicity (DLTs)","description":"Number of participant with DLT will be assessed. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematological or hematological toxicity.","timeFrame":"Cycle 1 (21 days)"}],"secondaryOutcomes":[{"measure":"Plasma Concentration of JNJ-88998377","description":"Plasma concentration of oral dose of JNJ-88998377 will be assessed.","timeFrame":"Up to first 12 weeks"},{"measure":"Area Under the Plasma Concentration Versus Time Curve During A Dosing Interval (τ) At Steady-State of JNJ-88998377","description":"Area under the plasma concentration versus time curve during a dosing interval (τ) at steady-state concentration of JNJ-88998377 will be reported.","timeFrame":"Up to first 12 weeks"},{"measure":"Maximum Plasma Concentration (Cmax) of JNJ-88998377","description":"Cmax of JNJ-88998377 will be reported.","timeFrame":"Up to first 12 weeks"},{"measure":"Minimum Plasma Drug Concentration (Cmin) of JNJ-88998377","description":"Cmin of JNJ-88998377 will be reported.","timeFrame":"Up to first 12 weeks"},{"measure":"Percentage of Participants With Overall Response (OR)","description":"OR is defined as the percentage of participants who have a best response of partial response (PR) or better per investigator assessment according to disease-specific response criteria.","timeFrame":"Up to 3 years 4 months"},{"measure":"Time to Response (TTR)","description":"TTR is defined for participants who achieved a response of PR or better as the time from the first dose of study treatment to the first response of PR or better per investigator assessment according to disease-specific response criteria.","timeFrame":"From first dose of study treatment until first response of PR or better (up to 3 years and 4 months)"},{"measure":"Duration of Response (DOR)","description":"DOR is defined for participants who achieved a response of PR or better as the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease or death.","timeFrame":"From date of documentation of first response of PR or better until progressive disease or death (up to 3 years and 4 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants have histologically or cytologically confirmed B-cell non-Hodgkin's Lymphoma (NHL) according to the 2022 World Health Organization (WHO) classification with relapsed or refractory disease\n* Participants have measurable disease or meet all requirements for adequate response assessment as defined by the appropriate disease response criteria at screening\n* Participants have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Participants have a life expectancy of greater than or equal to (\\>=) 12 weeks\n* Be willing and able to adhere to the lifestyle restrictions specified in the protocol\n\nExclusion Criteria:\n\n* Participant with active or prior history of B-cell NHL involving the central nervous system (CNS) and leptomeningeal involvement\n* History of malignancy (other than the disease under study in the cohort to which the participant is assigned) within 1 year prior to the first administration of study treatment as malignancies can interfere with study endpoints\n* Participant having known allergies, hypersensitivity, or intolerance to the excipients of JNJ-88998377\n* Participant had major surgery or had significant traumatic injury within 30 days before first dose of study treatment or has not recovered from surgery and must not have major surgery planned during the time the participant is receiving study treatment\n* Participant received an autologous stem cell transplant less than or equal to (\\<=) 3 months before the first dose of study treatment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Study Contact","role":"CONTACT","phone":"844-434-4210","email":"Participate-In-This-Study@its.jnj.com"}],"overallOfficials":[{"name":"Janssen Research & Development, LLC Clinical Trial","affiliation":"Janssen Research & Development, LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital","status":"RECRUITING","city":"Ankara","zip":"06200","country":"Turkey","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Ankara University Medical Faculty","status":"RECRUITING","city":"Ankara","zip":"06590","country":"Turkey","geoPoint":{"lat":39.91987,"lon":32.85427}},{"facility":"Koc University Medical Faculty","status":"RECRUITING","city":"Istanbul","zip":"34010","country":"Turkey","geoPoint":{"lat":41.01384,"lon":28.94966}}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency.\n\nAs noted on this site, requests for access to the study data can be submitted through Yale open Data Access (YODA) Project site at yoda.yale.edu","url":"https://www.janssen.com/clinical-trials/transparency"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000008223","term":"Lymphoma"},{"id":"D000008228","term":"Lymphoma, Non-Hodgkin"},{"id":"D000016393","term":"Lymphoma, B-Cell"}],"ancestors":[{"id":"D000009370","term":"Neoplasms by Histologic Type"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000008232","term":"Lymphoproliferative Disorders"},{"id":"D000008206","term":"Lymphatic Diseases"},{"id":"D000007160","term":"Immunoproliferative Disorders"},{"id":"D000007154","term":"Immune System Diseases"}],"browseLeaves":[{"id":"M11220","name":"Lymphoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"M18828","name":"Lymphoma, B-Cell","asFound":"B-Cell Non-Hodgkin Lymphoma","relevance":"HIGH"},{"id":"M11222","name":"Lymphoma, Non-Hodgkin","asFound":"Lymphoma, Non-Hodgkin","relevance":"HIGH"},{"id":"M12315","name":"Neoplasms by Histologic Type","relevance":"LOW"},{"id":"M11225","name":"Lymphoproliferative Disorders","relevance":"LOW"},{"id":"M11203","name":"Lymphatic Diseases","relevance":"LOW"},{"id":"M10206","name":"Immunoproliferative Disorders","relevance":"LOW"},{"id":"M10200","name":"Immune System Diseases","relevance":"LOW"},{"id":"T3543","name":"Lymphosarcoma","asFound":"Lymphoma","relevance":"HIGH"},{"id":"T640","name":"B-cell Lymphoma","asFound":"B-Cell Non-Hodgkin Lymphoma","relevance":"HIGH"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BC15","name":"Blood and Lymph Conditions"},{"abbrev":"BC20","name":"Immune System Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"Rare","name":"Rare Diseases"}]}},"hasResults":false}